{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Pharvaris N.V."},"Symbol":{"label":"Symbol","value":"PHVS"},"Address":{"label":"Address","value":"J.H. OORTWEG 21, LEIDEN, 2333 CH, Netherlands"},"Phone":{"label":"Phone","value":"+31 712036410"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications."},"CompanyUrl":{"label":"Company Url","value":"https://www.pharvaris.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Berndt A. E. Modig","title":"Chief Executive Officer & Executive Director"},{"name":"Peng Lu","title":"Chief Medical Officer & Head-Research & Technology"},{"name":"Stefan Abele","title":"Chief Technical Operations Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}